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Purpose: The purpose of this study was to investigate the prognostic effect of pulmonary function at the
beginning of postoperative radiotherapy (PORT) in non-small cell lung cancer (NSCLC).
Materials and methods: From January 2002 to December 2012, 115 patients with NSCLC who underwent
PORT and took the forced expiratory volume in 1 second (FEV1) at the beginning of PORT were analysed.
PORT began within 4–6 weeks following surgery, and the 3-dimensional conformal technique was used
with conventional fractionation. The high and low FEV1 groupswere divided by themedian absolute value
of FEV1 at the beginning of PORT, and we compared the clinical factors and survival between two groups.
Results: The median absolute value of FEV1 at the beginning of PORT was 1.68 L (range, 0.83–3.89), and
patients were divided into low and high FEV1 groups (<1.68 L versus P1.68 L). Patients in the low FEV1
group showed a lower preoperative FEV1 (mean, 1.94 L versus 2.73 L, p < 0.001) and received more pneu-
monectomy (36.8% versus 8.6%, p < 0.001) compared to the high FEV1 group. The overall median follow-up
time was 31 months (range, 3–110), and 5-year locoregional recurrence-free survival (LRRFS), distant
metastasis-free survival (DMFS) and overall survival (OS) were 52.4%, 48.9%, and 45.9%, respectively.
Five-year OS of the low FEV1 group was signiﬁcantly lower than that of the high FEV1 group (35.4% versus
56.9%, p = 0.002), and no signiﬁcant differences were found in LRRFS and DMFS. In a multivariate analysis,
the difference of OS between the low and high FEV1 groups remained signiﬁcant (Hazard Ratio = 2.04, CI,
1.18–3.55, p = 0.011).
Conclusions: The FEV1 at the beginning of PORT was an independent signiﬁcant prognostic factor in
patients with NSCLC who received PORT. Considering this analysis was limited to only patients receiving
PORT, further studies are warranted to compare the survival effect of postoperative pulmonary function
between groups with/without PORT.
 2014 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 113 (2014) 374–378
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/3.0/).The adjuvant role of postoperative radiotherapy (PORT) remains
controversial in the treatment of non-small cell lung cancer
(NSCLC). Meta-analysis of nine randomised trials evaluating the
role of PORT showed its detrimental effect on survival despite a
signiﬁcant decrease in the local control rate [1]. In this analysis,
the detrimental effect was prominent in patients with N0 and N1
stages and was less prominent in N2 disease. These stage-depen-
dent detrimental effects on survival suggest that PORT-induced
inter-current mortality is due to the old-fashioned technique of
radiotherapy with a high daily and total dose [2]. However, since
modern radiotherapy techniques have been implemented,radiation-induced morbidity and mortality have lessened [3] and
the beneﬁcial effect of PORT for N2 patients has been shown in a
large-scale retrospective analysis using the SEER database [4]. This
beneﬁcial effect for N2 disease was also demonstrated in the Adju-
vant Navelbine International Trialist Association (ANITA) trial [5].
Several recent retrospective studies evaluating the role of PORT
showed favourable results in patients with N2 involvement [6–
8]. These trends of a beneﬁcial effect of PORT may be a result of
the improvement of the therapeutic ratio using modern techniques
of radiotherapy, which minimise the irradiated dose to levels
found in normal tissues. Moreover, several studies have shown that
there is no excessive increase in the risk of death from intercurrent
disease (DID) [3], cardiopulmonary morbidity and quality
of life [9], and mortality from heart disease [10] in patients
treated with PORT using modern techniques. However, although
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Preoperative FEV1 (L) <0.001
Median (range) 2.61 (1.57–4.81) 1.96 (1.01–2.90)





















* COPD = chronic obstructive pulmonary disorder.
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the risk of death in the era of modern radiotherapy, it can have a
negative effect on long-term clinical outcomes in patients with
compromised cardiopulmonary function.
In our institution, we performed spirometry at the beginning of
PORT to assess the baseline level of pulmonary function after sur-
gery and excluded patients with compromised pulmonary function
who might have the potential risk of DID from PORT. Using this
PORT cohort, we aimed to investigate the prognostic signiﬁcance
of pulmonary function at the beginning of PORT on survival in
patients treated with PORT.
Methods and materials
From the tumour registry database of our institution, we iden-
tiﬁed 151 patients with NSCLC who received PORT after surgical
resection between January 2002 and December 2012. Of these
151 patients, we selected 115 patients who underwent spirometry
at the beginning of PORT for this study.
Lobectomy or pneumonectomy with mediastinal lymph node
dissection was performed, and PORT was delivered to patients with
a positive node (primarily N2) or positive resection margin on the
pathological specimen. PORT began within 4–6 weeks following
surgical resection. Three-dimensional conformal radiotherapy
(3-D CRT) was used, and radiotherapy was planned using a
mega-voltage photon beam (P6 MV). The clinical target volume
(CTV) included a bronchial stump, involved nodal stations and
subsequent draining of the involved nodal stations. The planning
target volume (PTV) was expanded from the CTV by a margin of
1–1.5 cm. Conventional fractionation (1.8–2.0 Gy/day) was used
with total dose of a 50.4–66 Gy according to the risk of loco-regio-
nal recurrence. The electively irradiated nodal stations were
excluded from the boost ﬁeld at a dose of 44–45 Gy. In the plan-
ning of PORT, dose-volume was constrained to a mean lung dose
of 20–25 Gy, and less than 25–30% of the lung volume that
received over 20 Gy (V20 < 25–30%). We did not modify these
constraints for those with lower FEV1. If adjuvant chemotherapy
was decided, then four to six cycles of platinum-based chemother-
apy were administered 3–4 weeks after the completion of PORT.
For the ﬁrst year after completion of PORT, patients were fol-
lowed-up every 3 months. For next 2 years, we followed-up every
6 months and then we performed an annual check-up. At each visit
of follow-up, we checked chest X-ray or chest CT scan. Annual
PET–CT was performed optionally.
Forced expiratory volume in 1 second (FEV1) was performed
just prior to computed tomography (CT) simulation for the assess-
ment of reserved lung function after surgical resection. To investi-
gate the prognostic value of FEV1, we divided the two groups
according to the median value of FEV1 and compared the clinical
parameters and survivals (locoregional-free survival, distant
metastasis-free survival and overall survival) between these two
groups. We did not perform survival analysis according to speciﬁc
causes of death due to retrospective data collection. Comparison
between the two groups was analysed using a chi-square test or
Fisher’s Exact Test for categorical variables and Student’s t-test or
Mann–Whitney U test for continuous variables.
The survival time was deﬁned by the duration between the date
of the surgical resection and the date of the last follow-up evalua-
tion or events and was calculated using the Kaplan–Meier method.
The log-rank test and Cox proportional hazards regression model
were used for univariate and multivariate analysis, respectively.
Two-sided p-values less than 0.05 were considered statistically sig-
niﬁcant. All statistical analyses were performed using IBM SPSS
statistics software, version 19.0 (IBM SPSS, New York, USA). This
study was reviewed and approved by the institutional review
board of Ajou University Hospital.Results
From a total of 115 patients, 94 (81.7%) patients were males,
and the age ranged from 30 to 77 years (median, 62). The types
of surgical resection were lobectomy in 89 patients (77.4%) and
pneumonectomy in 26 patients (22.6%). Pathological examination
revealed that adenocarcinoma was observed in 45 patients
(39.1%), and squamous cell carcinoma was found in 59 patients
(51.3%). Preoperative FEV1 ranged from 1.01 to 4.81 L (median,
2.38). Forty-one patients (35.7%) exhibited pathological N1 stage,
and 74 patients (64.3%) were pathological N2 stage. The total radi-
ation dose of PORT ranged from 30.6 to 75.0 Gy (median, 54 Gy).
Adjuvant chemotherapy was administered in 35 patients (30.4%),
and the cycle of chemotherapy ranged from 1 to 6 (median, 4).
The positive resection margin was shown in 10 patients (8.7%).
The absolute value of FEV1 at the beginning of PORT ranged
from 0.83 to 3.89 L (median, 1.68), and percentage value ranged
from 34 to 104% (median, 61). At the median absolute value of
FEV1, we classiﬁed the two groups as high FEV1 versus low FEV1
and patient characteristics between the two groups are summa-
rised in Table 1. Between the two groups, there were no signiﬁcant
differences in tumour histology, T-stage, N-stage, and resection
margin status. The age of patients in the high FEV1 group was sig-
niﬁcantly older than the low FEV1 group (mean age, 63.5 versus
55.8, p < 0.001). The proportion of females was higher in the low
FEV1 group (7.9% versus 29.8%, p = 0.002), but the proportion of
smokers was higher in the high FEV1 group (84.5% versus 68.4%,
Fig. 1. Kaplan–Meier survival curves. (A) Overall survival. (B) Locoregional recurrence-free survival. (C) Distant metastasis-free survival between high and low FEV1 groups.
376 Postoperative FEV1 in PORT for NSCLCp = 0.043). Preoperative FEV1 was signiﬁcantly higher in the high
FEV1 group compared to the low FEV1 group (mean FEV1, 2.73 L
versus 1.94 L, p < 0.001). Pneumonectomy was performed more
often in the low FEV1 group compared to the high FEV1 group
(8.6% versus 36.8%, p < 0.001). Radiation dose was signiﬁcantly dif-
ferent between the two groups (mean total dose, 55.7 Gy versus
53.4 Gy, p = 0.035), but the median of the total dose was 54.0 Gy
in both groups. Adjuvant chemotherapy was administered more
in the high FEV1 group compared to the low FEV1 group (41.4%
versus 19.3%, p = 0.010). Nine patients (7.8%) treated with steroids
due to symptomatic radiation pneumonitis (SRP) and there was no
statistical difference in the rate of SRP between two groups (7.5%
versus 8.6%, p = 1).
The median follow-up time of the 115 patients was 31 months
(range, 3–110), and the overall survival (OS) was 45.9% at 5 years.
All patients were followed-up at least once and subject to systemic
examination after PORT completion. The 5-year locoregional recur-
rence-free survival (LRRFS) and distant metastasis-free survival
(DMFS) were 52.4% and 48.9%, respectively. The overall survival
of the high FEV1 group was signiﬁcantly higher than that of the
low FEV1 group (5-year survival, 56.9% versus 35.4%, p = 0.002)
(Fig. 1A). There were no signiﬁcant differences in LRRFS and DMFS
between the high and low FEV1 groups (5-year LRRFS, 58.1% versus
45.4%, p = 0.286; 5-year DMFS, 52.7% versus 40.7%, p = 0.715)
(Fig. 1B and C).
Univariate analysis for other clinical factors demonstrated that
patients with pneumonectomy showed a signiﬁcant decrease in
overall survival compared to patients with lobectomy (p = 0.013).
Increased nodal stage (N2 disease) was a signiﬁcant adverse factor
affecting overall survival (p < 0.001), and administration of adju-
vant chemotherapy showed a trend of favourable overall survival
(p = 0.102). Gender, history of smoking, chronic obstructive pul-
monary disease, preoperative FEV1 (<2.38 L versus P2.38 L),
tumour histology, T-stage, positivity of resection margin andTable 2
Multivariable analysis of parameters affecting on overall survival.
Variable
FEV1 (L) <1.68/P1.68
Type of surgery Pneumonectomy/lobectomy
N stage N2/N1
Chemotherapy Yes/noirradiated total dose (<54.0 Gy versus P54.0 Gy) were not signiﬁ-
cant factors affecting overall survival. Multivariable analysis
revealed that FEV1 at the beginning of PORT (FEV1 < 1.68 L)
remained a signiﬁcant prognostic factor for overall survival
(HR = 2.04, p = 0.011) (Table 2).
We further analysed the 5-year OS of patients with low FEV1
according to different cut-offs (Fig. 2). There was a trend of
decreasing 5-year OS at the range below the cut-off FEV1 of 2.10 L.
Discussion
We hypothesised that pulmonary function at the beginning of
PORT can affect the outcomes in patients treated with PORT, and
our result showed that low values of FEV1 were an independent
negative prognostic factor on overall survival (<1.68 L versus
P1.68 L, HR = 2.04, p = 0.011). In addition, we calculated the 5-year
overall survival in patients with FEV1 less than the speciﬁc cut-off
value, and there was a trend of decreasing survival at the range
below the cut-off value of 2.1 L (Fig. 2). These results suggest that
pre-PORT pulmonary function below a speciﬁc level can be detri-
mental to overall survival in patients treated with PORT. Radiation
oncologists tend to exclude patients with poor pulmonary function
before the beginning of PORT because it is assumed that theywould
be susceptible to subtle lung toxicity induced by thoracic irradia-
tion. Generally, FEV1 lower than approximately 1.0 L after surgery
was adopted as an exclusion criterion [9]. In this study, patients
with an FEV1 lower than 0.8–1.0 L after surgerywere excluded from
performing PORT. However, even after excluding the patients with
poor FEV1, our results showed that the value of FEV1 remained a
prognostic factor. Between the high and low FEV1 groups, there
were no signiﬁcant differences in LRRFS and DMFS, but a signiﬁcant
difference in OS (Fig. 1). These results suggest that the value of FEV1
may be associated with the risk of death from intercurrent disease





Fig. 2. Five-year overall survival in the patients showing FEV1 less than speciﬁc cut-off value.
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the study population was restricted to patients treated with PORT.
Pulmonary function itself is known as a long-term predictor of mor-
tality in the general population [11]. Moreover, several studies have
reported that there is no PORT-induced worsening of pulmonary
function [9,12], which is different from that of patients treated with
deﬁnitive chemoradiotherapy, which demonstrated a decrease of
approximately 10% of pulmonary function [13]. These minimal or
lack of changes in pulmonary function after PORT may result from
the lower dose and smaller ﬁeld limited to mediastinum compared
to that of the deﬁnitive setting as well as the advanced techniques
of radiotherapy, which enable the minimisation of the irradiated
dose and volume of normal lung tissue. In these contexts, PORT
can be administered safely without compromising the pulmonary
function under the use of 3-dimensional conformal radiotherapy
techniques at doses of adjuvant setting (50–60 Gy). However,
although PORT can be feasible without a decrease in FEV1 [9] and
the risk of DID related to PORT was not excessively increased by
the modern radiotherapy technique [3], we should be cautious
about the minimal but substantial risk of DID, that may exist in
patients treated with PORT. Miles et al. suggested that RT-induced
mortality is strongly dependent on the size of the radiation ﬁeld
and at least partly offsets the beneﬁt of PORT using their simple
model based on clinical data [14]. In their study, the increase in
OS was assumed to be equal to the increase in cancer-speciﬁc sur-
vival minus the rate of mortality from PORT. This model suggested
that the tailored small ﬁeld-size targeting the areas most at risk of
recurrence might provide the highest therapeutic ratio, which can
result in an increase in OS byminimising the risk of RT-induced tox-
icities. This relationship between the increase in OS and the tailored
small ﬁeld-size also supports the minimal risk of RT-induced mor-
tality in the era of modern techniques. However, it also suggests
that the substantial risk of mortality from PORT exists even in a
small ﬁeld size, although it may be very small. Our hypothesis
was that the potential risk of DID can affect the OS in the patient
group with a relatively low FEV1 at the beginning of PORT, and
our results suggested that the substantial risk of DID might exist.
Thus, the effect of low FEV1 at the beginning of PORT should be
carefully assessed with regard to the risk and beneﬁt of PORT in
further studies.We analysed the prognostic effect of FEV1 at the beginning of
PORT because this timing is more proper to assess the functional
reserve than the FEV1 value prior to surgery. Initial pulmonary
function has been known as a prognostic factor in patients that
underwent surgery [15,16] and in advanced-stage patients treated
with chemotherapy or radiotherapy [17]. However, to the best of
our knowledge, previous studies investigating the effect of pul-
monary function at the beginning of PORT are rare. This may be
due to the unreliable or underestimated values related to the early
postoperative injury of the chest wall, which does not fully recover
within 4–6 weeks in most cases. However, although the result of
the postoperative pulmonary function test may not reﬂect the real
functional reserve, it can provide crude information about the gen-
eral postoperative condition and pulmonary function. Our results
suggest that the postoperative FEV1 could provide prognostic
information, and additional investigations should be performed
to elucidate the clinical importance of pulmonary function at the
beginning of PORT.
We compared the clinical variables between the low and high
FEV1 groups, which revealed the factors related to the level of
postoperative FEV1 (Table 1). The value of preoperative FEV1 was
higher in the high FEV1 group compared to the low FEV1 group,
and the proportion of patients that underwent a pneumonectomy
was signiﬁcantly higher in the low FEV1 group compared to the
high FEV1 group. This ﬁnding clearly showed that the initial pul-
monary function and the extent of surgical resection were closely
related to the level of postoperative pulmonary function. Poor pre-
operative pulmonary function and the extent of resection are
known as poor prognostic factors in NSCLC patients treated with
surgery [16]. In this study, preoperative FEV1 was not signiﬁcant
factor affecting overall survival (log-rank, p = 0.479), and the
extent of resection was a signiﬁcant factor in univariate analysis
(log-rank, p = 0.013). The extent of resection also did not sustain
its signiﬁcance in multivariate analysis (p = 0.084). The only signif-
icant prognostic factor was the value of FEV1 at the beginning of
PORT. These ﬁndings suggest that postoperative FEV1, which is clo-
sely related to the initial FEV1 and the extent of resection, is the
major determining factor for overall survival. For other variables,
patients in the low FEV1 group were predominantly female,
younger and mostly non-smokers compared to the high FEV1
378 Postoperative FEV1 in PORT for NSCLCgroup. Patients with NSCLC diagnosed at a young age tend to be
non-smoking females, and an aggressive treatment approach, such
as pneumonectomy, may be considered in such cases more often
than in older patients with similar clinical stages and conditions.
Patients in the low FEV1 group had good prognostic factors, such
as female and younger age [18], but the OS of the low FEV1 group
was signiﬁcantly lower compared to the high FEV1 group (Fig. 1A).
Although the proportion of administration of adjuvant chemother-
apy was higher in the high FEV1 group compared to the low FEV1
group (high FEV1 versus low FEV1, 41.4% versus 19.3%, p = 0.010),
adjuvant chemotherapy was not prognostic in multivariate analy-
sis (yes versus no, HR = 0.65, p = 0.226).
Our results suggest that the level of pulmonary function at the
beginning of PORT can be one of the important factors to be mon-
itored in the setting of randomised clinical trials. Recently pub-
lished meta-analyses reported that Linac-based modern PORT
was associated with signiﬁcantly lower risk of death and local
recurrence in stage IIIA-N2 NSCLC patients [19,20]. Furthermore,
these analyses suggest that the role of modern PORT should be
re-evaluated in stage III patients even after receiving (neo)-adju-
vant chemotherapy. For proper evaluation of the role of PORT in
randomised trials, several clinical factors should be monitored
because they may impact the results [21,22]. In this context, ran-
domised trials for modern PORT can be enhanced by stratiﬁcation
with postoperative pulmonary function.
The results of this study are limited by the single institutional
retrospective analysis, and the other pulmonary function parame-
ters could not be evaluated due to insufﬁcient data, particularly
with regard to the carbon monoxide diffusing capacity (DLCO).
We cannot exclude the possibility that disease relapses are under-
estimated in this study. Moreover, since extensive surgery may
lead to poor pulmonary function due to advanced disease, our
results may be biased by the fact that there might be more cancer
deaths in patients with poor pulmonary function. Nonetheless, this
study suggests that the postoperative pulmonary function (at the
beginning of PORT) can be a signiﬁcant prognostic factor affecting
OS in patients treated with PORT. The prognostic signiﬁcance of
postoperative pulmonary function should be investigated in large
clinical studies with more detailed parameters of pulmonary func-
tion, and it would be helpful to more precisely determine the vul-
nerability of patients from PORT and to minimise the risk of PORT
in these patients.
In conclusion, the FEV1 at the beginning of PORT was an inde-
pendent signiﬁcant prognostic factor in patients with NSCLC who
received PORT. Since our study was limited to those with PORT,
additional studies comparing two groups with/without PORT will
be helpful to understand the prognostic value of poor pulmonary
function after surgery.Conﬂicts of interest
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